P53, ATM mutations and the loss of PTEN are known to be associated with human prostate cancer radiosensitivity; however, they have not yet demonstrated the ability to predict which prostate cancers will eventually fail post radiotherapy. This evidence concerns the gene PTEN and prostate cancer.